Genflow Biosciences plc
Research Genflow Biosciences plc (GENF) on Bullrun: market cap GBX 11.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGENF
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 11.04M
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 1.42M
- Free cash flow-GBP 1.44M
Valuation Snapshot
latest market cap is GBX 11.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 1.42M | -GBP 1.44M | n/a | 0 | GBP 111.79K | n/a | -GBP 550.79K |
| FY2024 | GBP 0 | -GBP 1.59M | -GBP 1.08M | n/a | 0 | GBP 278.68K | n/a | -GBP 403.01K |
| FY2023 | GBP 0 | -GBP 1.86M | -GBP 1.66M | n/a | -0.01 | GBP 683.97K | n/a | GBP 499.69K |
| FY2022 | GBP 0 | -GBP 1.34M | -GBP 1.37M | n/a | 0 | GBP 2.36M | n/a | GBP 2.37M |
| FY2021 | GBP 0 | -GBP 988.20K | -GBP 747.38K | n/a | 0 | GBP 224.00K | n/a | GBP 55.12K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | GBX 11.04M | n/a | n/a | n/a |
About Genflow Biosciences plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genflow Biosciences plc's market cap?
Genflow Biosciences plc's market capitalization is GBX 11.04M.
What does Genflow Biosciences plc do?
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States.